Clinical Challenges: Treating AML With IDH1 and IDH2 Mutations
About 20% of acute myeloid leukemia (AML) harbors a mutation in the isocitrate dehydrogenase (IDH) genes, IDH1 or IDH2. Within the last decade, treatment for these patients “has changed significantly” with the development of first-in-class IDH1 and IDH2 inhibitors, said Tapan Kadia, MD, of the MD Anderson Cancer Center in Houston. Moreover, “treatment paradigms are […]